Fig. 4: Clobetasol-mediated reduction of pro-inflammatory cells in MN-depleted spinal cord.

a and b Representative pictures of Gfap immunostaining (a) and quantification of the number of positive cells for Gfap (b) in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord; data are shown as scatter dot plot and mean ± SEM of n ≥ 3 mice per group; *p-value < 0.05 versus HC; one-way ANOVA; scale bar in (a): 25 μm. c mRNA levels of Gfap in the spinal cord of in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord; data are shown as standard box-and-whiskers plot and mean ± SEM of n ≥ 3 mice per group; **p-value < 0.01 versus HC; one-way ANOVA. d Representative pictures and confocal deconvolutions of Gfap and P-Stat3 staining in HC, CTB-Sap vehicle, and CTB-Sap clobetasol spinal cord; arrowheads indicate astrocytes nuclei and in CTB-Sap vehicle P-Stat3 positive nuclei; scale bar: 20 μm. e Uniform manifold approximation and projection (UMAP) representation of the populations identified through flow-cytometry in the three different conditions. f Standard box-and-whiskers plot representing the five subpopulations that presented a significant modulation between HC, CTB-Sap vehicle, and CTB-Sap clobetasol mice. Plots show data from n = 4 mice per group; *p-value < 0.05 versus CTB-Sap vehicle; one-way ANOVA.